Millie Das Selected Research

Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)

1/2017

ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Millie Das Research Topics

Disease

13	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 09/2011
11	Neoplasms (Cancer) 11/2022 - 09/2011
6	Lung Neoplasms (Lung Cancer) 01/2022 - 06/2010
2	Neoplasm Metastasis (Metastasis) 11/2022 - 02/2013
2	Disease Progression 01/2022 - 10/2020
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 04/2020 - 01/2020
1	Malignant Pleural Effusion 11/2022
1	Brain Neoplasms (Brain Tumor) 01/2022
1	Heart Failure 12/2021
1	Supraventricular Tachycardia 12/2021
1	Cardiotoxicity 12/2021
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 04/2020
1	Neuroendocrine Carcinoma 04/2020
1	Dizziness (Lightheadedness) 04/2020
1	Confusion (Bewilderment) 04/2020
1	Sleepiness 04/2020
1	Fatigue 01/2018
1	Nausea 01/2018
1	Exanthema (Rash) 01/2018
1	Diarrhea 01/2018
1	Adenocarcinoma of Lung 01/2017
1	Circulating Neoplastic Cells 08/2012

Drug/Important Bio-Agent (IBA)

4	PlatinumIBA 01/2022 - 08/2012
4	Pharmaceutical PreparationsIBA 11/2021 - 09/2015
3	Bevacizumab (Avastin)FDA Link 01/2022 - 04/2012
3	Tyrosine Kinase InhibitorsIBA 01/2022 - 01/2018
2	osimertinibIBA 01/2022 - 12/2021
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 12/2021 - 09/2015
2	Circulating Tumor DNAIBA 01/2021 - 01/2020
2	B7-H1 AntigenIBA 01/2021 - 01/2020
2	Docetaxel (Taxotere)FDA Link 12/2014 - 09/2011
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2014 - 04/2012
2	Monoclonal AntibodiesIBA 12/2014 - 04/2012
2	Pemetrexed (MTA)FDA Link 09/2013 - 02/2013
1	Ado-Trastuzumab EmtansineIBA 01/2022
1	trastuzumab deruxtecanIBA 01/2022
1	Trastuzumab (Herceptin)FDA Link 01/2022
1	dabrafenibIBA 12/2021
1	brigatinibIBA 12/2021
1	trametinibIBA 12/2021
1	lorlatinibIBA 12/2021
1	alectinibIBA 12/2021
1	ceritinibIBA 12/2021
1	Gefitinib (Iressa)FDA Link 12/2021
1	CrizotinibIBA 12/2021
1	AfatinibIBA 12/2021
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2021
1	PM 01183IBA 11/2021
1	durvalumabIBA 01/2021
1	GlutaminaseIBA 12/2020
1	Immune Checkpoint InhibitorsIBA 10/2020
1	Tricyclic Antidepressive Agents (Tricyclic Antidepressants)IBA 04/2020
1	Desipramine (Pertofrane)FDA LinkGeneric 04/2020
1	Etoposide (VP 16)FDA LinkGeneric 01/2020
1	atezolizumabIBA 01/2020
1	ErbB Receptors (EGF Receptor)IBA 01/2019
1	XL647IBA 01/2018
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2017
1	4- amino- 5- fluoro- 3- (5- (4- methylpiperazin- 1- yl)- 1H- benzimidazol- 2- yl)quinolin- 2(1H)- oneIBA 09/2015
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 12/2014
1	RamucirumabIBA 12/2014
1	Biomarkers (Surrogate Marker)IBA 12/2014
1	motesanib diphosphateIBA 12/2012
1	Carboplatin (JM8)FDA LinkGeneric 09/2011

Therapy/Procedure

10	Therapeutics 11/2022 - 09/2013
6	Drug Therapy (Chemotherapy) 01/2022 - 08/2012
3	Immunotherapy 01/2022 - 01/2020
2	Radiotherapy 09/2011 - 06/2010
1	Time-to-Treatment 01/2022
1	Precision Medicine 01/2021
1	Chemoradiotherapy 09/2011
1	Radiofrequency Ablation 06/2010